Cystic Fibrosis Treatment Market Epidemiology Forecast to 2025 report provides Cystic Fibrosis risk factors, comorbidities,the global and historical trends as well as epidemiological market outlook for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data in US, France, Germany, Italy, Spain, UK, and Canada.
- Agency -.
The report Cystic Fibrosis Treatment Market Epidemiology Forecast to 2025 provides an overview of the risk factors, comorbidities, and the global and historical trends for CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data.
Moreover this report provides the in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Request Sample Report at www.reportsnreports.com/contacts/r….aspx?name=983930 .
- Agency -.
Cystic Fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat and digestive juices, and also causes severe damage to the lungs, digestive system and other organs. These secreted fluids are normally thin and slippery.
But in people with CF, a defective gene, known as the CFTR gene, causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways (Mayo Clinic, 2016).
In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries.
The UK has the greatest prevalence proportion of CF, which may be the result of a strong presence of the mutations in the country (UK CFR, 2014). Reports indicate that British and French ancestries are the origins of CF-causing mutations (Physicians Committee for Responsible Medicine, 2008).
National CF screenings are also imperative in detecting and capturing the true CF prevalence of a country.
Get This Research Report www.reportsnreports.com/contacts/d….aspx?name=983930 .
According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.
In the 7MM, based on registry data, our epidemiologists forecast that the diagnosed prevalent cases of CF will increase from 63,571 cases in 2015 to 73,368 cases in 2025, at an AGR of 1.54%. The US will have the highest number of diagnosed prevalent cases of CF among the 7MM throughout the forecast period, while Spain will have the lowest.
The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets.
Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older), specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection. The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Access This Report at www.reportsnreports.com/purchase.aspx?name=983930 .
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Executive Summary 5
2.1 Related Reports 12
3 Epidemiology 13
3.1 Disease Background 13
3.2 Risk Factors and Comorbidities 14
3.3 Global Trends 15
3.3.1 Diagnosed Incidence and Diagnosed Prevalence 16
3.4 Forecast Methodology 18
3.4.1 Sources Used 18
3.4.2 Forecast Assumptions and Methods 25
3.4.3 Sources Not Used 34
3.5 Epidemiological Forecast for CF (2015-2025) 35
3.5.1 Diagnosed Incident Cases, Based on Registry Data 35
3.5.2 Diagnosed Prevalent Cases, Based on Registry Data 38
3.5.3 CF Mortality, Based on Registry Data 46
3.5.4 Diagnosed Incident Cases, Adjusted for Underestimation 49
3.5.5 Diagnosed Prevalent Cases, Adjusted for Underestimation 52
3.5.6 CF Mortality, Adjusted for Underestimation 59
3.6 Discussion 62
3.6.1 Epidemiological Forecast Insight 62
3.6.2 Limitations of the Analysis 63
3.6.3 Strengths of the Analysis 64
4 Appendix 65
4.1 Bibliography 65
4.2 Physicians and Specialists Included in this Study 67
4.3 High-Prescribing Physician Survey 69
4.4 About the Authors 69
4.4.1 Epidemiologist 69
4.4.2 Reviewers 70
4.4.3 Global Director of Therapy Analysis and Epidemiology 71
4.4.4 Global Head of Healthcare 71
4.5 About GlobalData 72
4.6 About EpiCast 72
4.7 Contact Us 73
4.8 Disclaimer 73
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.
For more information: